Biota Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 80   

Articles published

BOTA 2.30 +0.03 (1.32%)
price chart
Biota Pharmaceuticals Inc Stock Downgraded (BOTA)
The gross profit margin for BIOTA PHARMACEUTICALS INC is currently lower than what is desirable, coming in at 34.92%. It has decreased significantly from the same period last year.
Related articles »  
Biota Pharmaceuticals: Recent Progress Illustrates Buying Opportunity Remains ...
While the termination of the BARDA contract in April 2014 that provided up $231 million for the development of laninamivir octanoate had a substantial negative effect on Biota in 2014 as it took away a source of major funding, the company has made ...
Massive Swings: Biota Pharmaceuticals, Inc. and Amicus Therapeutics, Inc.
Healthcare investors were presented with major movements in two small stocks today: Amicus Therapeutics (NASDAQ: FOLD ) popped almost 21% on strong phase 3 data for a Fabry disease drug, while Biota Pharmaceuticals (NASDAQ: BOTA ) collapsed ...
Related articles »  
Biota Pharmaceuticals to Present at the 27th Annual Roth Conference
ATLANTA, March 3, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"), a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening ...
Biota Pharmaceuticals Inc. And Venaxis Inc.: 2 Upcoming Biopharmaceuticals ...
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) is a biopharmaceutical company focused on the discovery and development of anti-infective products to prevent and treat a number of serious and potentially life-threatening infectious diseases.
Biota Pharmaceuticals to Present at the 2015 BIO CEO & Investor Conference
ATLANTA, Feb. 3, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"), a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening ...
Biota Pharmaceuticals to Acquire Anaconda Pharma
ATLANTA, Feb. 26, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals (Nasdaq:BOTA) (the "Company") announced today that it has entered into a definitive agreement to acquire Anaconda Pharma, a privately-held biotechnology company based in Paris, ...
Biota Pharmaceuticals: An Undervalued Long-Term Influenza Play (BOTA)
Biota is reducing headcount by 69% between June 2014 and June 2015, as well as closing its Melbourne facility, significantly decreasing cash burn.
Biota Pharmaceuticals, Inc. Files SEC Form SC 13G, Statement of Acquisition of ...
By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C. , by NewsRx journalists, a U.S.
Biota Pharmaceuticals relos HQ to Atlanta
A Northeast biopharmaceutical company is relocating its headquarters to Alpharetta as part of a consolidation and corporate restructuring.
Biota Pharmaceuticals to Make Alpharetta, GA Its New Home  GPB (blog)
Related articles »